Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis

Objectives To describe the population PKs of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis (SLED). Patients and methods This study was performed in ICUs of a university hospital. We collected blood samples during three consecutive days of SLED sessions in patients receiving ceftazidime. Concentration versus time curves were analysed using a population PKs approach with Pmetrics ® . Monte Carlo simulation for the first 24 h including a 6 h SLED session was performed with the final model. The fractional target attainment against the MIC of Pseudomonas aeruginosa was executed using targets of 50 and 100% fT  >   MIC . Results In total, 211 blood samples of 16 critically ill patients under SLED were collected. SLED treatments were 299.3 (68.4) min in duration. A two-compartment linear population PK model was most appropriate. The mean (SD) CL of ceftazidime on SLED, and off SLED were 5.32 (3.2), 1.06 (1.0) L/h respectively. The PTA for 50% fT  >   MIC for a dose of 1 g intravenously every 8 h was 98%. Assuming a target of 100% fT  >   MIC a dose of 2 g every 12 h covers isolates with MIC ≤8 mg/L with a PTA of 96%. Conclusion In critically ill patients receiving SLED, ceftazidime 1 g every 8 h and ceftazidime 2 g every 12 h appear to be sufficient for achieving traditional (50% fT  >   MIC ) and aggressive PD targets (100% fT  >   MIC ) for susceptible isolates (MIC ≤8 mg/L), respectively.

[1]  F. Taccone,et al.  Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy. , 2015, International journal of antimicrobial agents.

[2]  A. Jörres.  Akutes Nierenversagen – Auswahl der Nierenersatztherapie , 2015, Medizinische Klinik - Intensivmedizin und Notfallmedizin.

[3]  A. Jörres.  [Acute kidney injury: choice of the initial modality for renal replacement therapy]. , 2015, Medizinische Klinik, Intensivmedizin und Notfallmedizin.

[4]  T. Welte,et al.  Single- and multiple-dose pharmacokinetics and total removal of colistin in a patient with acute kidney injury undergoing extended daily dialysis. , 2014, The Journal of antimicrobial chemotherapy.

[5]  J. Rello,et al.  Roberts Risk factors for target non-attainment during empirical treatment with b-lactam antibiotics in critically ill patients , 2014 .

[6]  J. Mouton,et al.  Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. , 2013, The Journal of antimicrobial chemotherapy.

[7]  Jay Bartroff,et al.  Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[8]  L. E. Harris,et al.  Evaluation of antibiotic prescribing patterns in patients receiving sustained low‐efficiency dialysis: opportunities for pharmacists , 2013, The International journal of pharmacy practice.

[9]  Alan Schumitzky,et al.  Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R , 2012, Therapeutic drug monitoring.

[10]  M. Roberts,et al.  β‐Lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured review , 2012, Clinical and experimental pharmacology & physiology.

[11]  G. Houin,et al.  Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations. , 2012, British journal of clinical pharmacology.

[12]  V. Kaever,et al.  Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[13]  K. Urbánek,et al.  Vancomycin removal during low-flux and high-flux extended daily hemodialysis in critically ill septic patients. , 2012, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[14]  D. Paterson,et al.  Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients , 2011, BMC anesthesiology.

[15]  J. Roberts,et al.  Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. , 2011, Critical care clinics.

[16]  J. Chen,et al.  Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED). , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  Frédérique Jacobs,et al.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock , 2010, Critical care.

[18]  C. Kirkpatrick,et al.  Using Population Pharmacokinetics To Determine Gentamicin Dosing during Extended Daily Diafiltration in Critically Ill Patients with Acute Kidney Injury , 2010, Antimicrobial Agents and Chemotherapy.

[19]  H. Haller,et al.  Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  W. Haefeli,et al.  Pharmacokinetics of linezolid in septic patients with and without extended dialysis , 2010, European Journal of Clinical Pharmacology.

[21]  G. Houin,et al.  Population Pharmacokinetics of Ceftazidime in Intensive Care Unit Patients: Influence of Glomerular Filtration Rate, Mechanical Ventilation, and Reason for Admission , 2009, Antimicrobial Agents and Chemotherapy.

[22]  T. Welte,et al.  Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  Jerome J. Schentag,et al.  Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. , 2008, International journal of antimicrobial agents.

[24]  T. Welte,et al.  Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. , 2007, The Journal of antimicrobial chemotherapy.

[25]  D. Fliser,et al.  Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[26]  J. Bertrand,et al.  Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation , 2006, Critical care.

[27]  D. Fliser,et al.  Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis* , 2006, Critical care medicine.

[28]  U. Maggiore,et al.  Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure , 2004, Critical care medicine.

[29]  T. Vree,et al.  Dosage adjustment for ceftazidime in patients with impaired renal function , 2004, European Journal of Clinical Pharmacology.

[30]  K. Ratheiser,et al.  Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. , 2002, The Journal of antimicrobial chemotherapy.

[31]  P. Palevsky,et al.  Determinants of Ceftazidime Clearance by Continuous Venovenous Hemofiltration and Continuous Venovenous Hemodialysis , 2000, Antimicrobial Agents and Chemotherapy.

[32]  K. Okumura,et al.  Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis. , 1985, Chemotherapy.

[33]  J. Fillastre,et al.  Pharmacokinetics of ceftazidime in normal and uremic subjects , 1984, Antimicrobial Agents and Chemotherapy.

[34]  J. Blumer,et al.  Determination of ceftazidime in biological fluids by using high-pressure liquid chromatography , 1983, Antimicrobial Agents and Chemotherapy.